BioSyent Stock

BioSyent Assets per Share

The Total Assets per Share of BioSyent (RX.V) as of Sep 11, 2026 is 4.19 CAD. In the previous year, Total Assets per Share was 3.50 CAD — a change of 19.54% (higher).

Assets per Share

4.19CAD

YoY

19.54%

Last updated:

Total Assets per Share of BioSyent is 2026 4.19 CAD. Total Assets per Share of BioSyent was 2025 3.50 CAD. It decreases by 19.54% higher compared to the previous year.

The BioSyent Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
2.64 CAD
Jan 1, 2019
2.62 CAD
Jan 1, 2020
2.84 CAD
Jan 1, 2021
3.15 CAD
Jan 1, 2022
3.43 CAD
Jan 1, 2023
3.52 CAD
Jan 1, 2024
3.50 CAD
Jan 1, 2025
4.19 CAD
The BioSyent Assets per Share history
YEARAssets per ShareYoY
4.19CAD+19.54%
3.50CAD-0.41%
3.52CAD+2.58%
3.43CAD+8.93%
3.15CAD+10.71%
2.84CAD+8.42%
2.62CAD-0.72%
2.64CAD+24.23%
2.13CAD+30.43%
1.63CAD+31.76%
1.24CAD+37.23%
0.90CAD
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Total Assets per Share of BioSyent is 4.19 CAD in 2026.

Total Assets per Share of BioSyent changed from 3.50 CAD to 4.19 CAD, representing a 19.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share BioSyent since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

Other — BioSyent

All Key Metrics — BioSyent